

FIRST LIGHT 21 April 2020

### **RESEARCH**

# BOB Economics Research | Weekly Wrap

Oil falls, equities recover

Infosys | Target: Rs 730 | +12% | ADD

Subpar operating performance, annual guidance suspended

# Logistics | Q4FY20 Preview

Expect an anaemic quarter

#### **SUMMARY**

# India Economics: Weekly Wrap

Global equity markets closed higher on the hope of successful treatment to Covid-19 to hit the markets soon enough. Yields fell as macro data points to steep slowdown with IMF warning of a sharp recession. China's Q1CY20 GDP contracted by 6.8%. India's 2Y yield fell by more than 40bps as RBI Governor indicated room for further rate cuts. We expect another 50bps rate cut as economy slows down to 1.5% in the year. We also see stimulus for MSMEs, more liquidity for impacted sectors and RBI buying government bonds.

## Click here for the full report.

# Infosys

Infosys (INFO) reported a lacklustre Q4FY20 operating performance marked by a miss on both revenue and margins. Deal TCV at US\$ 1.6bn was modest and carried a caveat of likely ramp-up delays. Suspended annual guidance, especially on operating margins, adds a blind spot in a crucial year for margin recovery. We trim FY21/FY22 EPS estimates by 15%/16% and revise our Mar'21 TP to Rs 730 (vs. Rs 840 earlier), set at an unchanged FY22E P/E of 18x. Retain ADD but prefer TCS and HCL Tech over INFO.

### Click here for the full report.

## **TOP PICKS**

### LARGE-CAP IDEAS

Company	Rating	Target
Bajaj Finance	Buy	3,000
<u>Cipla</u>	Buy	570
Eicher Motors	Buy	25,000
Petronet LNG	Buy	330
Reliance Industries	Buy	1,500

#### MID-CAP IDEAS

Company	Rating	Target
<u>Alkem Labs</u>	Buy	2,870
Greenply Industries	Buy	145
Laurus Labs	Buy	510
<u>Transport Corp</u>	Buy	255
Ashok Leyland	Sell	64

Source: BOBCAPS Research

## **DAILY MACRO INDICATORS**

Indicator	Current	2D (%)	1M (%)	12M (%)
US 10Y yield (%)	0.64	2bps	(44bps)	(192bps)
India 10Y yield (%)	6.35	(9bps)	8bps	(107bps)
USD/INR	76.38	0.5	(2.9)	(10.1)
Brent Crude (US\$/bbl)	28.08	0.9	(2.3)	(61.0)
Dow	24,242	3.0	14.2	(8.7)
Shanghai	2,838	0.7	2.1	(13.2)
Sensex	31,589	3.2	3.3	(19.3)
India FII (US\$ mn)	16 Apr	MTD	CYTD	FYTD
FII-D	(162.8)	(933.1)	(10,692.6)	(933.1)
FII-E	(337.6)	0.4	(6,602.5)	0.4

Source: Bank of Baroda Economics Research

## **BOBCAPS** Research

research@bobcaps.in





# Logistics: Q4FY20 Preview

Already reeling under a domestic consumption slowdown, the Indian logistics industry has now taken a severe blow from Covid-19-led trade disruptions. We forecast revenue and EBITDA declines for all our coverage companies in Q4FY20, with TCIEXP being the only player expected to post earnings growth (3.5% YoY) due to reduced taxes. The sharp plunge in auto volumes would hurt auto-focused 3PL companies (MLL, TRPC). We reiterate our preference for companies with strong balance sheets; TCIEXP is our top pick.

Click here for the full report.

EQUITY RESEARCH 21 April 2020



# **WEEKLY WRAP**

20 April 2020

# Oil falls, equities recover

Global equity markets closed higher on the hope of successful treatment to Covid-19 to hit the markets soon enough. Yields fell as macro data points to steep slowdown with IMF warning of a sharp recession. China's Q1CY20 GDP contracted by 6.8%. India's 2Y yield fell by more than 40bps as RBI Governor indicated room for further rate cuts. We expect another 50bps rate cut as economy slows down to 1.5% in the year. We also see stimulus for MSMEs, more liquidity for impacted sectors and RBI buying government bonds.

Sameer Narang | Jahnavi chief.economist@bankofbaroda.com

## **Markets**

- Bonds: Except Japan and China, global yields closed lower as macro data points to a steep slowdown. IMF has warned of a severe recession. US 10Y yield fell by 8bps (0.64%) as retail sales, factory output and home sales disappointed. Oil prices fell by 10.8% (US\$ 28/bbl) as OPEC projected global oil demand to drop by 6.8 mn bpd in CY20. India's 10Y yield fell by 14bps (6.35%). India's 2Y yield fell by more than 40bps as RBI Governor indicated room for further rate cuts. System liquidity surplus was at Rs 4.8tn, same as last week.
- Currency: Global currencies closed mixed. DXY rose by 0.3% in the week as investors fear the economic impact of the pandemic will be worse than anticipated. Rising US jobless claims and sharp drop in US retail sales and industrial orders also dented sentiment. CNY fell by 0.5% as China's GDP growth contracted by 6.8%. INR ended the week lower by 0.1% after touching a fresh record low at 76.79/\$. FPI outflows were US\$ 539mn.
- Equity: Apart from FTSE, other global indices closed higher in the week led by hopes of a possible vaccine for COVID-19 and as countries begin to open up their economies. Dow (2.2%) posted gains for second week in a row. Sensex (1.4%) too ended in green supported by liquidity boosting measures by RBI. Cap goods and metal stocks gained the most.
- Upcoming key events: Markets will track COVID-19 cases. Pace of increase has moderated to 564k this week from 599k last week. Apart from this, flash PMI readings of major economies (US, Eurozone and Japan) are scheduled to be released. On the domestic front, markets will await fresh stimulus from government to combat the crisis.





**ADD**TP: Rs 730 | ▲ 12%

**INFOSYS** 

IT Services

21 April 2020

# Subpar operating performance, annual guidance suspended

Infosys (INFO) reported a lacklustre Q4FY20 operating performance marked by a miss on both revenue and margins. Deal TCV at US\$ 1.6bn was modest and carried a caveat of likely ramp-up delays. Suspended annual guidance, especially on operating margins, adds a blind spot in a crucial year for margin recovery. We trim FY21/FY22 EPS estimates by 15%/16% and revise our Mar'21 TP to Rs 730 (vs. Rs 840 earlier), set at an unchanged FY22E P/E of 18x. Retain ADD but prefer TCS and HCL Tech over INFO.

Ruchi Burde | Seema Nayak research@bobcaps.in

**Disappointing performance:** Akin to peers, a partial Covid-19 hit in the last few weeks of March led to a 0.8% QoQ CC decline in INFO's revenue (-1.4% QoQ in dollar terms) vs. consensus estimates of 0.6% QoQ CC growth. Revenue contraction stemmed from reduction in traditional services revenue (-3.6% QoQ in dollar terms) even as digital revenue growth (+1.7% QoQ in dollar terms) was at its slowest pace since the company started this quarterly disclosure in Q1FY18. EBIT margins at 21.2% shed 80bps QoQ, rounding off FY20 at 21.3% – towards the lower end of the guided range of 21-23%.

Modest deal wins, caveat of likely ramp-up delays: Deal win TCV at US\$ 1.6bn reflected seasonal moderation with a 9% QoQ decline, albeit up 5% YoY. New deal share increased to 56% vs. 32% in Q3, though management indicated likely ramp-up delays and the possibility of slower deal conversion during the Covid-19 turmoil.

**Suspended outlook:** As with peers such as Wipro and Cognizant, INFO has also suspended its annual outlook, both for revenue and operating margins. FY21 was to be critical for management's three-year strategic programme that aimed at recouping operating margins during the year. But Covid-led uncertainty and a suspended margin outlook have added disappointing blind spots.

<b>KFY</b>	FIN	1 A L	<b>JC</b>	ΙΔΙ	5

Y/E 31 Mar	FY18A	FY19A	FY20P	FY21E	FY22E
Total revenue (Rs mn)	705,220	826,760	907,910	912,792	991,163
EBITDA (Rs mn)	190,100	208,890	222,680	229,136	255,368
Adj. net profit (Rs mn)	160,280	154,100	167,350	155,792	172,692
Adj. EPS (Rs)	36.9	35.4	39.0	36.3	40.3
Adj. EPS growth (%)	17.3	(4.0)	10.3	(6.9)	10.8
Adj. ROAE (%)	23.9	24.5	26.5	22.6	22.9
Adj. P/E (x)	17.7	18.5	16.7	18.0	16.2
EV/EBITDA (x)	13.5	12.6	11.9	11.6	10.4

Source: Company, BOBCAPS Research

Ticker/Price	INFO IN/Rs 653
Market cap	US\$ 37.1bn
Shares o/s	4,349mn
3M ADV	US\$ 88.0mn
52wk high/low	Rs 847/Rs 509
Promoter/FPI/DII	13%/35%/52%

Source: NSE

## STOCK PERFORMANCE



Source: NSE





### **LOGISTICS**

Q4FY20 Preview

20 April 2020

# Expect an anaemic quarter

Already reeling under a domestic consumption slowdown, the Indian logistics industry has now taken a severe blow from Covid-19-led trade disruptions. We forecast revenue and EBITDA declines for all our coverage companies in Q4FY20, with TCIEXP being the only player expected to post earnings growth (3.5% YoY) due to reduced taxes. The sharp plunge in auto volumes would hurt auto-focused 3PL companies (MLL, TRPC). We reiterate our preference for companies with strong balance sheets; TCIEXP is our top pick.

Sayan Das Sharma research@bobcaps.in

**Unprecedented trade slowdown:** Coming on the heels of soft EXIM trade and a prolonged domestic consumption slowdown, the Covid-19 outbreak has aggravated the woes of Indian logistics companies. The national lockdown from 25 March has ushered in an unprecedented slowdown in domestic trade, as corroborated by high frequency indicators for the month— (1) EXIM trade has plunged 31% YoY in Mar'20— the steepest fall on record, and (2) major port traffic has slipped 5% YoY. Upcoming trade indicators are likely to be even worse.

Anaemic earnings...: We expect our logistics coverage to report revenue/EBITDA declines in Q4FY20, consequent to the sharp plunge in domestic and EXIM trade. Economic activity typically picks up in March, and hence the pandemic-related disruptions in the last two weeks of the month are likely to have a significant impact on growth and profitability. We forecast a median revenue decline of 7% YoY for our logistics coverage in Q4 vs. a 2% increase in 9MFY20.

...barring TCIEXP: TCI Express (TCIEXP) is likely to be the only company to post higher YoY earnings, led by a lower corporate tax rate. Auto-focused players – Mahindra Logistics (MLL) and Transport Corp (TRPC, SCS division) – could see a sharp dip in revenue after a steep plunge in auto OEM sale volumes in Mar'20. Restrictions on vehicle movement have hurt road freight operators (TRPC's freight vertical and VRL Logistics). Soft global container trade will hit EXIM-oriented players – Container Corp has reported a 4% drop in Q4 volumes.

**Prefer companies with strong balance sheets:** With sustained growth recovery at least a couple of quarters away, we continue to recommend that investors stay with companies which have quality balance sheets and established market positions. We reiterate TCIEXP as our top pick, followed by VRLL, MLL and TRPC. We revise our FY20-FY22 earnings estimates down for MLL and AGLL, factoring in the Covid-19 impact on near-term growth prospects and profitability.

#### RECOMMENDATION SNAPSHOT

Ticker	Rating
AGLL IN	ADD
CCRIIN	ADD
MAHLOG IN	BUY
TCIEXP IN	BUY
TPRC IN	BUY
VRLL IN	BUY
AAALILOC AALI	

MAHLOG = MLL





## Disclaimer

#### Recommendations and Absolute returns (%) over 12 months

BUY - Expected return >+15%

ADD - Expected return from >+5% to +15%

**REDUCE** - Expected return from -5% to +5%

SELL - Expected return <-5%

Note: Recommendation structure changed with effect from 1 January 2018 (Hold rating discontinued and replaced by Add / Reduce)

#### Rating distribution

As of 31 March 2020, out of 91 rated stocks in the BOB Capital Markets Limited (BOBCAPS) coverage universe, 54 have BUY ratings, 20 have ADD ratings, 7 are rated REDUCE, 9 are rated SELL and 1 is UNDER REVIEW. None of these companies have been investment banking clients in the last 12 months.

#### Analyst certification

Each of the analysts mentioned in this research report certify, with respect to the sections of the report for which they are responsible, that (1) all of the views expressed in this report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOBCAPS.

#### Important disclosures

This product is a compilation of previously published research notes. To view the complete report along with the associated Analyst certifications and Company-specific disclosures, please click on the hyperlink accompanying each excerpt.

### General disclaimers

BOBCAPS is engaged in the business of Institutional Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS has obtained registration as a Research Entity under SEBI (Research Analysts) Regulations, 2014, having registration No.: INH000000040 valid till 03 February 2020. BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities —that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

EQUITY RESEARCH 21 April 2020

#### **FIRST LIGHT**



We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may act as market makers or assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

In the US, this material is only for Qualified Institutional Buyers as defined under rule 144(a) of the Securities Act, 1933. No part of this document may be distributed in Canada or used by private customers in the United Kingdom.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

#### Other disclosures

BOBCAPS does not have any financial interest in the subject company. BOBCAPS does not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS is not engaged in any market making activities for the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

EQUITY RESEARCH 21 April 2020